Related Experiment Video

Updated: Jun 25, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Targeting BRAF pathway in low-grade serous ovarian cancer

Chiara Perrone1, Roberto Angioli2, Daniela Luvero2

  • 1Department of Gynecological, Obstetrical and Urological Sciences, Sapienza University of Rome, Rome, Italy.

Journal of Gynecologic Oncology
|May 20, 2024
PubMed

Insights

Targeted therapy combining BRAF and MEK inhibitors shows promise for ovarian carcinomas, particularly low-grade serous ovarian carcinoma, addressing resistance to conventional treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • RAS-RAF-MEK-ERK pathway mutations are implicated in various cancers, including ovarian carcinomas.
  • Low-grade serous ovarian carcinoma (LGSOC) exhibits resistance to standard chemotherapy despite favorable survival rates.
  • Specific genetic profiles, such as KRAS/BRAF mutations, differentiate LGSOC from high-grade serous carcinoma.

Purpose of the Study:

  • To review the efficacy and safety of combined BRAF and MEK inhibitor therapy in ovarian carcinomas.
  • To specifically focus on the application of this combination therapy in LGSOC.
  • To explore potential mechanisms of resistance and therapeutic strategies.

Main Methods:

  • Literature review of preclinical studies and clinical trials.
  • Analysis of data on BRAF and MEK inhibitor combinations.
  • Focus on studies involving ovarian carcinoma patients, especially LGSOC.

Main Results:

  • BRAF inhibitors are approved for BRAF-mutated tumors, but resistance is a concern.
  • Combined BRAF and MEK inhibition has shown potential in preclinical models to delay resistance.
  • Clinical investigation of combination therapy is ongoing for ovarian carcinomas.

Conclusions:

  • Combined BRAF and MEK inhibitors represent a promising therapeutic strategy for ovarian carcinomas, including LGSOC.
  • This approach may overcome resistance mechanisms associated with single-agent BRAF inhibition.
  • Further clinical evaluation is crucial to establish the safety and efficacy profile of this combination therapy.
Keywords:
BRAF Protein, HumanMEK InhibitorOvarian Neoplasms

More Related Videos

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

8.1K
Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

17.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K